People: BTG PLC (BTG.L)
Dr. Susan Elizabeth Foden, Ph.D., serves as Independent Non-Executive Director of the Company. Susan appointed to the Board in March 2015. She is a member of the Remuneration Committee. Susan currently holds non-executive roles with BerGenBio ASA, Evgen Pharma plc and Vectura Group plc, and is an advisory board member for CD3 (a joint initiative between Leuven University and the European Investment Fund). Susan brings extensive industry experience to the BTG Board with a strong track record of having assisted in the development of a number of businesses in the sector. She was Investor Director with the venture capital firm Merlin Biosciences, was formerly CEO of the technology transfer company, Cancer Research Campaign Technology Ltd and was Head of Academic Liaison at Celltech Ltd.
|Total Annual Compensation, GBP||54,000|
|Restricted Stock Award, GBP||--|
|Long-Term Incentive Plans, GBP||--|
|All Other, GBP||3,000|
|Fiscal Year Total, GBP||57,000|